Literature DB >> 21225916

Kaposi sarcoma in South African children.

D Cristina Stefan1, David K Stones, Linda Wainwright, Robert Newton.   

Abstract

BACKGROUND: The incidence of Kaposi's sarcoma (KS) in sub-Saharan Africa, increased tens of times since the onset of the AIDS epidemic. There is, however, very little literature concerning the clinical features of this disease, its management and outcome in HIV-positive children in Africa. This study describes retrospectively the clinical presentation of the malignancy, its management and outcome, in a series of HIV-positive children. PATIENTS AND METHODS: Seventy children with KS and HIV infection were admitted consecutively from January 1998 to December 2009 in South African hospitals. Clinical data were extracted from tumor registries and patient records and analyzed.
RESULTS: The average age in this series was 73 months. The males/females ratio was 1.59:1. Skin lesions were present in 36 out of 63 cases (57.14%), followed by lymph node lesions (28 cases, 44.44%). The mean CD4+ lymphocyte count was 440 (SD = 385). The average CD4+ percentage was 12.20% (SD = 9.13). Only 14 patients (20%) were taking combined antiretrovirals at the time of diagnosis; a further 35 were given HIV treatment after diagnosis. Thirty-two patients (45.71%) survived only 4 months on average; 10 were lost to follow-up; and 28 (40%) were alive, with an average follow-up of 16 months. Antiretrovirals improved survival (P = 0.001).
CONCLUSIONS: The often present skin lesions facilitated the diagnosis; lymphadenopathy was less frequently seen than skin lesions. Antiretroviral drugs were associated with higher survival rate. The mortality remains high in spite of antiretrovirals and cytostatics.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21225916     DOI: 10.1002/pbc.22903

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

Review 1.  A Review of Human Herpesvirus 8, the Kaposi's Sarcoma-Associated Herpesvirus, in the Pediatric Population.

Authors:  Dorothy E Dow; Coleen K Cunningham; Ann M Buchanan
Journal:  J Pediatric Infect Dis Soc       Date:  2013-09-04       Impact factor: 3.164

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

3.  Long-term cancer risk among people diagnosed with AIDS during childhood.

Authors:  Edgar P Simard; Meredith S Shiels; Kishor Bhatia; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-11-08       Impact factor: 4.254

4.  Long-term outcomes for children and adolescents with Kaposi sarcoma.

Authors:  Allison Silverstein; William Kamiyango; Jimmy Villiera; Erin C Peckham-Gregory; Casey L McAtee; Michael E Scheurer; Carrie M Cox; Carrie L Kovarik; Liane R Campbell; Carl E Allen; Parth S Mehta; Peter N Kazembe; Nmazuo W Ozuah; Nader Kim El-Mallawany
Journal:  HIV Med       Date:  2021-10-11       Impact factor: 3.094

5.  Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study.

Authors:  Nader Kim El-Mallawany; William Kamiyango; Jeremy S Slone; Jimmy Villiera; Carrie L Kovarik; Carrie M Cox; Dirk P Dittmer; Saeed Ahmed; Gordon E Schutze; Michael E Scheurer; Peter N Kazembe; Parth S Mehta
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

Review 6.  Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8.

Authors:  Carolyn C Jackson; Mark A Dickson; Mahan Sadjadi; Antoine Gessain; Laurent Abel; Emmanuelle Jouanguy; Jean-Laurent Casanova
Journal:  Pediatr Blood Cancer       Date:  2015-10-15       Impact factor: 3.167

7.  Clinical and laboratory characteristics, staging, and outcomes of individuals with AIDS-associated Kaposi's sarcoma at an university hospital.

Authors:  Catarina Tenório de Lima; Paulo Sérgio Ramos de Araújo; Heberton Medeiros de Teixeira; Josemir Belo Dos Santos; Vera Magalhães da Silveira
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

8.  Primary Kaposi's sarcoma of the nasal cavity: a case report and review of the literature.

Authors:  Karima Mouden; Mouna Khmou; Saida Loughmari; Afaf Semmar; Hanan El Kacemi; Basma El Khannoussi; Tayeb Kebdani; Sanaa Elmajjaoui; Noureddine Benjaafar
Journal:  Clin Sarcoma Res       Date:  2016-03-17

Review 9.  Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives.

Authors:  Nader Kim El-Mallawany; Casey L McAtee; Liane R Campbell; Peter N Kazembe
Journal:  Pediatric Health Med Ther       Date:  2018-04-19

10.  Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease.

Authors:  Nader Kim El-Mallawany; Jimmy Villiera; William Kamiyango; Erin C Peckham-Gregory; Michael E Scheurer; Carl E Allen; Casey L McAtee; Alejandra Legarreta; Dirk P Dittmer; Carrie L Kovarik; Elizabeth Y Chiao; Stephen C Martin; Nmazuo W Ozuah; Parth S Mehta; Peter N Kazembe
Journal:  Infect Agent Cancer       Date:  2018-11-09       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.